Literature DB >> 6885204

A crossover study after oral and intravenous administration of theophylline in male volunteers (absolute bioavailability of Afonilum tablets).

H S Kaumeier, O H Kehrhahn, G Neugebauer, D Schuppan, J A Schwarz, A H Staib.   

Abstract

Seven normal male volunteers received an injection of 208 mg theophylline-anhydride (Solosin) each for 4 min, and a 225-mg single oral dose (Afonilum) on separate occasions. The concentration of unchanged theophylline was analyzed over a 24-h period in plasma and over a 48-h period in urine, after both dosage forms. A two-compartment model was required to describe the i.v. plasma concentration-time course in all seven subjects. A one-compartment model sufficed to account for the decay of the oral plasma concentrations in five of the subjects. The mean plasma t 1/2 after i.v. dosing was 6.5 h (3.5-9 h), and the mean plasma t 1/2 after oral doses was 5.9 h (3-8.3 h). The calculated mean total of 23% (11-70%) of the i.v. dose was excreted in the urine, and the mean total excretion after the oral dose was 15% (7-44%). The absolute bioavailability of Afonilum was 108 +/- 11%.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6885204

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  4 in total

Review 1.  An inequality-constrained least-squares deconvolution method.

Authors:  D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1989-04

2.  Estimation of drug absorption rates using a deconvolution method with nonequal sampling times.

Authors:  K Iga; Y Ogawa; T Yashiki; T Shimamoto
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

Review 3.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 4.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.